Objective:To prepare novel targeted lipid nanobubbles（MEB-NBs）that can be loaded with exosomes（Exo），and test the property and explore the specific invitro target-seeking ability of MEB-NBs. Methods:The core lipid nanobubbles（NBs）were prepared using mechanical oscillation methods，and Exo was connected to the NBs through membrane fusion. The target antibody MYH6 was linked to the NBs using a phospholipid coupling covalent method，resulting in the preparation of targeted lipid nanobubbles MEB-NBs loaded with Exo. The morphology，particle size，and surface potential of the prepared lipid nanobubbles MEB-NBs were observed，and the co-loading of Exo and NBs was verified using laser confocal and fluorescence resonance energy transfer techniques. The in vitro imaging capability and biosafety of MEB-NBs were evaluated，and the loading rate and drug content of Exo carried by MEB-NBs were measured. The ability of MEB-NBs to specifically target hiPSC-CMs cells was observed using flow cytometry，small animal in vivo imaging systems，and laser confocal microscopy. Results:The average particle size of the prepared MEB-NBs was（597.10 ± 47.70）nm，the surface potential was（-11.70 ± 0.21）mV，and the concentration was（2.43 ± 0.06）×10 7/ml. Laser confocal microscopy and FRET results confirmed that the Exo was effectively connected with the NBs；When the Exo concentration was 250 μg/ml，the Exo loading rate and drug loading of MEB-NBs were both 73.8%，and the results of laser confocal microscopy showed that MEB-NBs could be effectively targeted to hiPSC-CMs cells. MEB-NBs were well developed in vitro and had good biological safety. Conclusions:This study constructs novel Exo-loaded targeted lipid nanobubbles（MEB-NBs）that demonstrate stable physicochemical properties and ultrasound imaging capabilities. The developed MEB-NBs precisely target hiPSC-CMs cells，providing an innovative drug delivery system with enhanced therapeutic efficacy for Exo-based therapies.

Objective:To prepare novel targeted lipid nanobubbles（MEB-NBs）that can be loaded with exosomes（Exo），and test the property and explore the specific invitro target-seeking ability of MEB-NBs. Methods:The core lipid nanobubbles（NBs）were prepared using mechanical oscillation methods，and Exo was connected to the NBs through membrane fusion. The target antibody MYH6 was linked to the NBs using a phospholipid coupling covalent method，resulting in the preparation of targeted lipid nanobubbles MEB-NBs loaded with Exo. The morphology，particle size，and surface potential of the prepared lipid nanobubbles MEB-NBs were observed，and the co-loading of Exo and NBs was verified using laser confocal and fluorescence resonance energy transfer techniques. The in vitro imaging capability and biosafety of MEB-NBs were evaluated，and the loading rate and drug content of Exo carried by MEB-NBs were measured. The ability of MEB-NBs to specifically target hiPSC-CMs cells was observed using flow cytometry，small animal in vivo imaging systems，and laser confocal microscopy. Results:The average particle size of the prepared MEB-NBs was（597.10 ± 47.70）nm，the surface potential was（-11.70 ± 0.21）mV，and the concentration was（2.43 ± 0.06）×10 7/ml. Laser confocal microscopy and FRET results confirmed that the Exo was effectively connected with the NBs；When the Exo concentration was 250 μg/ml，the Exo loading rate and drug loading of MEB-NBs were both 73.8%，and the results of laser confocal microscopy showed that MEB-NBs could be effectively targeted to hiPSC-CMs cells. MEB-NBs were well developed in vitro and had good biological safety. Conclusions:This study constructs novel Exo-loaded targeted lipid nanobubbles（MEB-NBs）that demonstrate stable physicochemical properties and ultrasound imaging capabilities. The developed MEB-NBs precisely target hiPSC-CMs cells，providing an innovative drug delivery system with enhanced therapeutic efficacy for Exo-based therapies.

Objective:To prepare dual-targeted lipid ultrasound microbubbles loaded with ANM33 (HA-PANBs) and evaluate its feasibility in targeting foam cells by stages and achieving precise intracellular drug release in vitro. Methods:The dual-targeteded lipid ultrasound microbubbles were designed with nanobubbles (NBs) as the microbubble core, hyaluronic acid (HA) as the first-stage targeting ligand for damaged endothelial cells, aptamer PM1 as the second-stage targeting moiety for foam cells, and ANM33 as the therapeutic factor. Simultaneously with the characterization of the lipid bubbles, the stability and in vitro contrast-enhanced ultrasound imaging capability were detected. Then a co-culture model of damaged human umbilical vein endothelial cells (HUVEC) and macrophages (RAW264.7, MΦ) was established, combined with flow cytometry, oil red O staining and small animal in vivo imaging to evaluate the ability of HA-PANBs in targeting foam cells precisely and releasing ANM33. Results:The HA-PANBs exhibited regular morphology and good structural stability, with a particle size of (1 357.53±140.20)nm and a surface potential of (-5.61±0.73)mV. HA, PM1 and ANM33 were effectively connected. In the damaged HUVEC/MΦ co-culture system, the HA-PANBs group demonstrated the best targeting effect on foam cells, with an effective uptake of (80.65±2.12)%, which was 56.74% higher than that of the NBs group. Oil red O staining revealed that the cholesterol efflux capacity of foam cells in the HA-PANBs group was significantly better than that in the NBs group, the results were statistically different [(629.80±21.99) a.u.vs (1 071.00±55.49)a.u., P<0.05]. Conclusions:The dual-targeted lipid ultrasound microbubbles (HA-PANBs) can precisely target foam cells and significantly enhance their cholesterol efflux, providing a new strategy for the early non-invasive diagnosis and treatment of atherosclerosis.